文献速递消化道肿瘤放疗放疗物理与技术

局部晚期与复发直肠癌术中近距离放疗的临床选择策略与评估

Clinical selection strategy for and evaluation of intra-operative brachytherapy in patients with locally advanced and recurrent rectal cancer.
PubMed 文献 · Radiother Oncol · 2021-03-17

该研究评估了132例局部晚期或复发直肠癌患者术中近距离放疗(IOBT)的临床选择策略,其中122例切除肿瘤。临床判断正确率为72.6%,但26.5%的复发直肠癌患者被不恰当地省略IOBT。IOBT毒性可接受,建议对所有存在R1切除风险的复发直肠癌患者行IOBT。

要点

  • 临床判断R1切除的总体正确率为72.6%。
  • 复发直肠癌中26.5%患者被不恰当地省略IOBT。
  • IOBT毒性可比且可接受,推荐用于R1风险的复发直肠癌。

核心结论

  • 临床判断正确率为72.6%,但26.5%的复发直肠癌患者IOBT被不恰当地省略。
  • IOBT毒性可比且可接受,推荐对所有存在R1切除风险的复发直肠癌患者行IOBT作为挽救治疗。

研究设计与样本

  • 2007年2月至2018年5月纳入132例计划手术并备行IOBT的局部晚期或复发直肠癌患者。
  • 通过术中切缘检查和MR成像判断切除是否根治,必要时行冰冻切片,疑似R1切除时给予IOBT(1×10 Gy)。

主要发现

  • 122例患者切除肿瘤,42例接受IOBT,其中54.8%(23例)病理证实R1切除。
  • 76例省略IOBT的R0切除患者中,17.1%(13例)病理证实R1切除。
  • 4例省略IOBT的患者临床判断为R1/2切除。
  • 局部晚期直肠癌中,58.3%(14例)过度治疗(R0但接受IOBT),10.9%(5例)治疗不足(R1但未接受IOBT)。
  • 复发直肠癌中,26.5%(9例)治疗不足。

关键数值与推荐

  • IOBT剂量为1×10 Gy,用于疑似R1切除的患者。
  • 临床判断正确率72.6%(88例),局部晚期直肠癌过度治疗率58.3%,治疗不足率10.9%;复发直肠癌治疗不足率26.5%。

临床怎么用

  • 对局部晚期或复发直肠癌患者,术中应综合切缘检查和MR成像判断R1风险,必要时行冰冻切片。
  • 对存在R1切除风险的复发直肠癌患者,推荐行IOBT(1×10 Gy)作为挽救治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: A radical resection of locally advanced rectal cancer (LARC) or recurrent rectal cancer (RRC) can be challenging. In case of increased risk of an R1 resection, intra-operative brachytherapy (IOBT) can be applied. We evaluated the clinical selection strategy for IOBT. MATERIALS AND METHODS: Between February 2007 and May 2018, 132 LARC/RRC patients who were scheduled for surgery with IOBT standby, were evaluated. By intra-operative inspection of the resection margin and MR imaging, it was determined whether a resection was presumed to be radical. Frozen sections were taken on indication. In case of a suspected R1 resection, IOBT (1 × 10 Gy) was applied. Histopathologic evaluation, treatment and toxicity data were collected from medical records. RESULTS: Tumour was resected in 122 patients. IOBT was given in 42 patients of whom 54.8% (n = 23) had a histopathologically proven R1 resection. Of the 76 IOBT-omitted R0 resected patients, 17.1% (n = 13) had a histopathologically proven R1 resection. In 4 IOBT-omitted patients, a clinical R1/2 resection was seen. In total, correct clinical judgement occurred in 72.6% (n = 88) of patients. In LARC, 58.3% (n = 14) of patients were overtreated (R0, with IOBT) and 10.9% (n = 5) were undertreated (R1, without IOBT). In RRC, 26.5% (n = 9) of patients were undertreated. CONCLUSION: In total, correct clinical judgement occurred in 72.6% (n = 88). However, in 26.5% (n = 9) RRC patients, IOBT was unjustifiedly omitted. IOBT is accompanied by comparable and acceptable toxicity. Therefore, we recommend IOBT to all RRC patients at risk of an R1 resection as their salvage treatment.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Dijkstra EA, Mul VEM, Hemmer PHJ, et al. Clinical selection strategy for and evaluation of intra-operative brachytherapy in patients with locally advanced and recurrent rectal cancer. Radiother Oncol. 2021. PMID: 33741470. doi:10.1016/j.radonc.2021.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。